https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=12467
No pharmaceutical opinion available for this interaction.
Rifapentin can induce the metabolism (CYP 3A4) and decrease the plasma concentration of Dolutegravir.
Possible decrease of clinical efficacy.
Juluca : Concomitant administration contraindicated.
–
–
Avoid association. Choose an alternative.
See rifabutin + dolutegravir and rifampin + dolutegravir.
–
–
–
Ref #3343 : This study was stopped prematurely due to serious toxicities, possibly related to high isoniazid exposure (67-92% higher than expected), observed in 2 of 3 subjects receiving 3 doses of weekly isoniazid/rifapentine (wHP) with once daily dolutegravir. Limited PK data from these subjects showed decreased dolutegravir exposure by 46% and Cmin values by 74% with wHP co-administration. Researchers suggest to avoid co-administration.